JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265326

Human UBE2D4 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

UBE2D4 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Sanger Sequencing - Human UBE2D4 knockout HeLa cell line (AB265326)
  • Sanger seq

Unknown

Sanger Sequencing - Human UBE2D4 knockout HeLa cell line (AB265326)

Homozygous : 1 bp insertion in exon 2.

Sanger Sequencing - Human UBE2D4 knockout HeLa cell line (AB265326)
  • Sanger seq

Lab

Sanger Sequencing - Human UBE2D4 knockout HeLa cell line (AB265326)

Sequencing chromatogram displaying sequence edit in exon 2

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265326-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265326 Human UBE2D4 knockout HeLa cell line", "number":"AB265326-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265326-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265326-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265326-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265326 Human UBE2D4 knockout HeLa cell line", "number":"AB265326-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265326-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265326 Human UBE2D4 knockout HeLa cell line", "number":"AB265326-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265326-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265326 Human UBE2D4 knockout HeLa cell line", "number":"AB265326-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
UBE2D4
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

UBE2D4 also known as UBC4/5 homolog is an enzyme with a molecular weight of approximately 16 kDa. This protein functions as a ubiquitin-conjugating enzyme that plays a role in the ubiquitination process helping to transfer ubiquitin from an E1 activating enzyme to an E3 ligase substrate protein. UBE2D4 is expressed in various tissues throughout the body including high expression in skeletal muscle and liver. Its mechanical role is critical in tagging proteins for degradation via the proteasome.
Biological function summary

The ubiquitin-conjugating enzyme plays a role in protein homeostasis by facilitating the ubiquitin-proteasome system a complex that includes E1 E2 and E3 enzymes. UBE2D4 acts in concert with specific E3 ligases to regulate cell cycle progression and transcriptional regulation. This process ensures the removal of misfolded or damaged proteins thereby maintaining protein quality within cells. Its involvement in diverse cellular pathways highlights the enzyme's importance in controlling cellular activities.

Pathways

UBE2D4 operates in the ubiquitin-mediated proteolysis and cell cycle regulatory pathways. These pathways control protein turnover and degradation ensuring cellular equilibrium. UBE2D4 collaborates with E3 ligases like MDM2 within these pathways influencing proteins like p53 which is important for cell cycle control and apoptosis. The interconnectedness with MDM2 emphasizes UBE2D4's role in key cellular events.

Alterations or malfunctions in UBE2D4 activity have linked it to cancer and neurodegenerative diseases. Misregulation of p53 related proteins via UBE2D4 alterations may promote unrestrained cell proliferation seen in cancers. Furthermore abnormal ubiquitination processes associating with pathways including UBE2D4 contribute to the accumulation of protein aggregates in neurodegenerative disorders including Alzheimer's disease. The relationship with MDM2 and p53 proteins highlights UBE2D4's significant role in disease pathogenesis.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com